News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Emisphere Technologies, Inc. (EMIS) and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen(R) Technology


3/18/2010 10:17:46 AM

CEDAR KNOLLS, N.J. & BRISBANE, Australia--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere’s Eligen® Technology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES